NASDAQ:VRAX Virax Biolabs Group (VRAX) Stock Price, News & Analysis → An utter travesty (From The Freeport Society) (Ad) Free VRAX Stock Alerts $1.73 +0.05 (+2.98%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$1.60▼$1.8050-Day Range$0.61▼$1.9752-Week Range$0.60▼$5.45Volume461,984 shsAverage Volume830,158 shsMarket Capitalization$2.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Virax Biolabs Group alerts: Email Address Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Virax Biolabs Group Stock (NASDAQ:VRAX)Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.Read More VRAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRAX Stock News HeadlinesJune 7, 2024 | investorplace.comWhy Is Virax Biolabs (VRAX) Stock Down 15% Today?June 6, 2024 | investorplace.comWhy Is Virax Biolabs (VRAX) Stock Up 115% Today?April 25, 2024 | prnewswire.comVirax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024April 16, 2024 | finance.yahoo.comVirax Biolabs to Participate at ESCMID Global 2024March 15, 2024 | prnewswire.comVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyDecember 21, 2023 | finance.yahoo.comVirax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID PatientsDecember 14, 2023 | msn.comVirax Biolabs announces 1-for-10 share consolidationDecember 14, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces 1-for-10 Share ConsolidationDecember 7, 2023 | msn.comVirax Biolabs files for up to $30M mixed securities shelfOctober 2, 2023 | thestreet.comVirax Biolabs Group Ltd OrdSeptember 21, 2023 | finance.yahoo.comVRAX: Virax Biolabs transformative preventive diagnostic platform supports higher stock price.September 12, 2023 | finance.yahoo.comVirax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts WebinarSeptember 1, 2023 | finance.yahoo.comVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth MomentumAugust 3, 2023 | finance.yahoo.comNasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 BidJune 21, 2023 | finance.yahoo.comVRAX: Virax Biolabs releases shareholder letter and financial results for the fiscal year ending March 31, 2023.May 5, 2023 | finance.yahoo.comVRAX: UPDATE: Innovative biotechnology company developing a potentially groundbreaking immunology platform based around proprietary T-Cell testing technology.May 4, 2023 | finance.yahoo.comVirax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science ParkApril 21, 2023 | nasdaq.comVirax Biolabs Group Limited Ordinary Shares (VRAX)March 10, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 8, 2023 | benzinga.comVirax Biolabs Group Stock (NASDAQ:VRAX), DividendsMarch 8, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 7, 2023 | msn.comVirax Biolabs Stock Soars On Avian Flu Test Kit Agreement: What's Going On?March 7, 2023 | finance.yahoo.comEXCLUSIVE: Virax Biolabs Starts Distribution Of Avian Flu Test Kits In EuropeMarch 7, 2023 | benzinga.comWhy Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 7, 2023 | prnewswire.comVirax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test KitSee More Headlines Receive VRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/13/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:VRAX CUSIPN/A CIK1885827 Webviraxbiolabs.com Phone44-0-20-7788-7414FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.59 Quick Ratio7.56 Sales & Book Value Annual Sales$10,000.00 Price / Sales268.15 Cash FlowN/A Price / Cash FlowN/A Book Value$5.73 per share Price / Book0.30Miscellaneous Outstanding Shares1,550,000Free Float854,000Market Cap$2.68 million OptionableNot Optionable Beta1.55 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. James Foster (Age 39)Chairman & CEO Comp: $347.5kMr. Jason D. Davis (Age 52)Chief Financial Officer Comp: $237.5kMr. Mark James Ternouth (Age 56)Chief Technical Officer & Director Comp: $90kDr. Tomasz Evan George (Age 40)Chief Scientific Officer Comp: $194kDr. Nigel McCracken M.Sc.Ph.D., Chief Operating OfficerMs. Joel YeungAccounting ManagerMr. Clement MonteilHead of Scientific Research & DevelopmentMr. James WangHead of Procurement & SourcingMs. Lily FuHead of Supply ChainMore ExecutivesKey CompetitorsBiomericaNASDAQ:BMRAMyMD PharmaceuticalsNASDAQ:MYMDNavidea BiopharmaceuticalsNYSE:NAVBIDEXX LaboratoriesNASDAQ:IDXXLantheusNASDAQ:LNTHView All Competitors VRAX Stock Analysis - Frequently Asked Questions How have VRAX shares performed in 2024? Virax Biolabs Group's stock was trading at $1.46 on January 1st, 2024. Since then, VRAX stock has increased by 18.5% and is now trading at $1.73. View the best growth stocks for 2024 here. Are investors shorting Virax Biolabs Group? Virax Biolabs Group saw a increase in short interest in May. As of May 31st, there was short interest totaling 47,000 shares, an increase of 7,733.3% from the May 15th total of 600 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.7% of the company's stock are sold short. View Virax Biolabs Group's Short Interest. When did Virax Biolabs Group's stock split? Virax Biolabs Group's stock reverse split before market open on Monday, December 18th 2023. The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virax Biolabs Group IPO? Virax Biolabs Group (VRAX) raised $7 million in an initial public offering (IPO) on Thursday, July 21st 2022. The company issued 1,400,000 shares at a price of $5.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Virax Biolabs Group? Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRAX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.